首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1896968

全球細胞和基因治療市場：按治療類型、載體、生產方法、最終用戶和地區劃分－市場規模、產業動態、機會分析和預測（2025-2035 年）

Global Cell and Gene Therapy Market: By Therapy Type, Vector Type, Manufacturing Type, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2035

出版日期: 2025年12月24日 | 出版商:

Astute Analytica | 英文 340 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

細胞和基因療法市場正呈現強勁且加速成長的態勢，預計到 2024 年將達到約 365 億美元。如此可觀的市場規模反映了先進療法在各個疾病領域的快速普及和應用範圍的不斷擴大。展望未來，預計到 2035 年，該市場將快速成長至約 1,831 億美元，2026 年至 2035 年的複合年增長率 (CAGR) 為 17.5%。

推動這一成長趨勢的關鍵因素有很多。技術創新是其中最重要的因素，基因編輯、載體開發和生產流程的不斷進步使得更有效、更安全、更易於規模化的療法成為可能。這些突破性進展正在擴大可治療疾病的範圍，改善臨床療效，從而增加患者的治療機會並提升市場潛力。此外，慢性病和罕見疾病領域持續存在的未滿足醫療需求，也持續推動對新型治療方案的需求。

市場趨勢

細胞和基因治療市場由諾華、吉利德（透過其子公司Kite）、輝瑞、bluebird bio和安進等大型公司主導。儘管市場集中度較高，但競爭仍然激烈，各公司積極尋求策略聯盟，並探索創新的融資模式，以應對先進療法的高成本。一個顯著的例子是按療效付費協議（OBA）的使用，該協議將支付與CAR-T療法等療法的實際臨床療效掛鉤，其中包括Yescarta和Zolgensma等知名產品。

2025年12月，產業合作取得了重大進展，SCTbio和Fortrea宣佈建立策略聯盟，以加速細胞和基因療法的開發和交付。此次合作凸顯了旨在匯集專業知識、擴大生產能力並簡化從研究到患者使用的流程的合作趨勢日益增長。

同時，全球科學創新領導者賽默飛世爾科技（Thermo Fisher Scientific）於2025年11月迎來了一個重要的里程碑，其位於費城的東海岸旗艦先進治療協作中心（ATxCC）正式啟用。該中心將是該公司在美國的第二個ATxCC，與位於加州卡爾斯巴德的現有中心形成互補。

2025年10月，龍沙（Lonza）推出新的TheraPEAK®產品－AmpliCell®細胞激素和TheraPEAK® 293-GT®培養基，進一步鞏固了其市場地位。這些符合GMP標準的工具旨在提高從研究到生產的整個流程的一致性和生物學相關性。

核心驅動因素

細胞和基因治療市場的快速顯著增長正在推動生產能力的顯著擴張，並促進了強大的合約開發和生產組織 (CDMO) 生態系統的發展。隨著越來越多的療法進入臨床試驗階段並接近商業化，對符合良好生產規範 (GMP) 的專業生產設施的需求至關重要。確保生產流程符合嚴格的品質和安全標準，對於確保這些複雜的療法能夠惠及患者至關重要。

新興機會

在基因醫學領域，體內基因編輯正成為一種革命性的趨勢，從根本上改變了治療介入的實施方式。傳統方法需要從患者體內提取細胞，在體外進行修飾，然後再重新輸注，而體內基因編輯可以直接在患者體內進行 DNA 修飾。這種方法簡化了治療流程，無需複雜的細胞提取和回輸程序，使治療更容易實施，也更容易獲得。體內基因編輯的營運優勢顯著。更有效率的治療方案可減少治療準備和實施所需的時間和資源。

優化障礙

全球私人資金對細胞和基因療法的投入減少，對市場成長構成重大挑戰。私人投資在推動該領域的創新和進步方面發揮著至關重要的作用，尤其是在許多進展高度依賴早期研發的情況下。由於來自創投、私募股權公司和其他私人管道的資金流入減少，企業在獲得資助研發管線、進行臨床試驗以及將新療法推向市場所需的資源方面面臨著重大障礙。資金的減少可能會減緩科學發現的步伐，並延緩有前景的療法從實驗室走向商業化的進程。

產業價值鏈分析
- 材料供應商
- 製造商
- 經銷商
- 終端用戶
行業展望
- 2020-2035年全球細胞與基因治療市場
- 細胞和基因治療概述：市場趨勢和區域趨勢
PESTLE分析
波特五力分析
- 供應商議價能力
- 買方議價能力
- 替代品威脅
- 新進入者威脅
- 競爭強度
市場成長與展望
- 市場收入估算與預測（2020-2035年）
- 依療法劃分的價格趨勢分析
市場吸引力分析
- 依療法劃分
- 按地區劃分
- 可操作的洞見（分析師建議）

第四章：競爭格局概覽

市場集中度
公司市佔率分析（價值，2025 年）
競爭格局分析與基準分析
- 主要公司（按地區劃分）

第五章：全球細胞與基因治療市場分析

市場動態與趨勢
- 成長驅動因素
- 限制因素
- 機遇
- 主要趨勢
市場機會概述
依療法類型劃分
- 主要發現
- 市場規模與預測（2020-2035）
- 細胞療法
- 基因療法
依適應症/治療領域劃分
- 主要發現
- 市場規模及預測，2020-2035
- 腫瘤學
- 實體瘤
- 遺傳性疾病
- 神經系統疾病
- 心血管疾病
- 眼科
- 肌肉骨骼/骨科疾病
- 傳染病
- 代謝性疾病
- 其他
依載體型別（基因遞送法）劃分
- 主要發現
- 市場規模及預測，2020-2035
- 病毒載體
- 非病毒載體
依生產方式劃分類型
- 主要發現
- 市場規模及預測（2020-2035 年）
- 內部研發
- 合約研發生產機構 (CDMO)
- 混合模式
- 其他
依最終用戶劃分
- 關鍵洞察
- 市場規模及預測（2020-2035 年）
- 醫院和專科診所
- 學術和研究機構
- 製藥和生技公司
- 政府/公共衛生機構
- 其他
按地區劃分
- 關鍵洞察
- 市場規模及預測（2020-2035 年）

第六章北美細胞與基因治療市場分析

第七章：歐洲細胞與基因治療市場分析

第八章：亞太地區細胞與基因治療市場分析

第九章：中東和非洲細胞和基因治療市場分析

第十章：南美洲細胞與基因治療市場分析

第十一章：公司簡介

ALLOGENE THERAPEUTICS
安進公司 (Amgen Inc.)
安斯泰來藥廠 (Astellas Pharma Inc.)
Atara Biotherapeutics, Inc.
拜耳公司 (Bayer AG)
BioMarin
Bluebird Bio, Inc.
百時美施貴寶公司 (Bristol-Myers Squibb Company)
新基公司 (Celgene Corporation)
Cellectis
吉利德科學公司 (Gilead Sciences, Inc.)
羅氏公司 (Hoffmann-La Roche)有限公司
ImmunoACT
強生公司
Krystal Biotech, Inc.
諾華公司
Orchard Therapeutics plc
Sana Biotechnology
uniQure NV.
Vericel Corporation
其他

第十二章附錄

簡介目錄

Product Code: AA12251611

The cell and gene therapy market is demonstrating a robust and accelerating growth trajectory, with its value reaching an estimated US$ 36.5 billion in 2024. This impressive market size reflects the rapid adoption and expanding applications of these advanced therapies across a range of medical conditions. Looking ahead, projections indicate that the market will soar to an estimated valuation of US$ 183.1 billion by 2035, representing a compound annual growth rate (CAGR) of 17.5% during the forecast period from 2026 to 2035.

Several key factors are driving this upward curve. Technological innovation remains at the forefront, with ongoing advances in gene editing, vector development, and manufacturing processes enabling more effective, safer, and scalable therapies. These breakthroughs are expanding the range of treatable diseases and improving clinical outcomes, thereby enhancing both patient access and market potential. Additionally, the persistent unmet medical needs in chronic and rare diseases continue to fuel demand for novel treatment options.

Noteworthy Market Developments

The cell and gene therapy market is led by major players such as Novartis, Gilead (through its Kite subsidiary), Pfizer, Bluebird Bio, and Amgen. Although the market is semi-consolidated, it remains highly competitive, with companies actively engaging in strategic partnerships and exploring innovative financing models to manage the high costs associated with advanced therapies. One notable example is the use of outcomes-based agreements (OBAs), which link payment to the real-world performance of therapies like CAR-T treatments, including well-known products such as Yescarta and Zolgensma.

In December 2025, the industry witnessed a significant collaboration as SCTbio and Fortrea announced a strategic partnership aimed at accelerating the development and delivery of cell and gene therapies. This collaboration highlights the growing trend of alliances designed to combine expertise, expand manufacturing capabilities, and streamline the path from research to patient access.

Meanwhile, Thermo Fisher Scientific Inc., a global leader in scientific innovation, marked a major milestone in November 2025 by officially opening its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia. This facility represents the company's second ATxCC in the United States, complementing its existing center in Carlsbad, California.

In October 2025, Lonza further strengthened its position in the market by launching two new TheraPEAK(R) products: AmpliCell(R) Cytokines and TheraPEAK(R) 293-GT(R) Medium. These GMP-compliant tools are designed to enhance consistency and biological relevance across the entire research and manufacturing continuum.

Core Growth Drivers

The rapid and tremendous growth of the cell and gene therapy market is fueling a substantial expansion in manufacturing capabilities, alongside the development of a robust Contract Development and Manufacturing Organization (CDMO) ecosystem. As an increasing number of therapies advance through clinical trials and move closer to commercialization, the demand for specialized production facilities that comply with Good Manufacturing Practices (GMP) has become critically important. Ensuring that manufacturing processes meet stringent quality and safety standards is essential for the successful delivery of these complex therapies to patients.

Emerging Opportunity Trends

In vivo gene editing has emerged as a transformative trend in the field of genetic medicine, fundamentally changing how therapeutic interventions are delivered. Unlike traditional approaches that involve removing cells from a patient's body, modifying them externally, and then reintroducing them, in vivo gene editing allows for direct alterations to a patient's DNA within their body. This method simplifies the treatment process by eliminating the need for complex cell extraction and reinfusion procedures, thereby making therapy administration more straightforward and accessible. The logistical advantages of in vivo gene editing are significant. Treatments can be delivered more efficiently, reducing the time and resources required to prepare and administer therapy.

Barriers to Optimization

A decline in global private funding for cell and gene therapy presents a significant challenge to the market's growth trajectory. Private investment plays a critical role in driving innovation and progression within this sector, particularly because many advancements rely heavily on early-stage research and development. When capital inflows from venture capitalists, private equity firms, and other private sources diminish, companies face substantial obstacles in securing the necessary resources to fund their research pipelines, conduct clinical trials, and bring new therapies to market. This reduction in funding can slow down the pace of scientific discovery and delay the transition of promising therapies from the laboratory to commercial availability.

Detailed Market Segmentation

By Therapy Type, the cell therapy segment captured a significant portion of the revenue share in the cell and gene therapy market in 2024, solidifying its leadership position within the industry. This dominance is largely attributable to a surge of regulatory approvals and increased investment fueling the rapid development and commercialization of cell-based treatments. The approval of new therapies by regulatory agencies not only validates the safety and efficacy of these innovative products but also encourages further research and confidence among investors, healthcare providers, and patients.

By Indication / Therapeutic Area, the infectious disease segment is projected to command the largest market share within the cell and gene therapy industry, reflecting the expanding application of these advanced therapeutic approaches in combating a wide array of infectious conditions. The increasing burden of infectious diseases worldwide, including viral, bacterial, and parasitic infections, has driven a surge in demand for innovative treatments that can effectively target pathogens and enhance immune responses. Cell and gene therapies offer promising solutions by enabling precise interventions at the molecular and cellular levels, which traditional treatments often cannot achieve.

By Vector Type (Gene Delivery Method), the in vivo delivery method dominated in 2024 by capturing the largest revenue share. This prominence is primarily attributed to its high efficiency and versatility, which make it suitable for a broad range of therapeutic applications. Unlike ex vivo methods, where cells are modified outside the body and then reintroduced, in vivo delivery involves directly administering genetic material into the patient's body. This approach simplifies the treatment process, reduces logistical challenges, and holds promise for treating a wider variety of diseases, including those affecting tissues and organs that are difficult to access externally.

By end-users, the cancer care centers hold the lion's share of the cell and gene therapy market, reflecting the high concentration of cancer treatments within this specialized healthcare segment. These centers are at the forefront of adopting advanced therapies as oncologists increasingly integrate cell and gene therapies into their treatment protocols. The growing prevalence of cancer worldwide, coupled with advancements in personalized medicine, has made these therapies a cornerstone for addressing complex and aggressive malignancies that were previously difficult to treat effectively.

Segment Breakdown

By Therapy Type

Cell Therapy
Stem Cell Therapy
T-Cells
Dendritic Cells
NK Cells
Gene Therapy
In-vivGene Therapy
Ex-vivGene Therapy
Gene Editing Therapies
RNA-Based Therapies
Others

By Indication / Therapeutic Area

Oncology
Solid Tumors
Genetic Disorders
Neurological Disorders
Cardiovascular Diseases
Ophthalmology
Musculoskeletal / Orthopedic Disorders
Infectious Diseases
Metabolic Disorders
Others

By Vector Type (Gene Delivery Method)

Viral Vectors
Adeno-Associated Virus (AAV)
Lentivirus
Retrovirus
Herpes Simplex Virus (HSV)
Adenovirus
Others
Non-Viral Vectors
Lipid Nanoparticles (LNPs)
Naked DNA/RNA Plasmids
Electroporation
Gene gun/microinjection
CRISPR-Cas Delivery Systems (non-viral)
Others

By Manufacturing Type

In-house
Contract Development & Manufacturing Organizations (CDMOs)
Hybrid Models (e.g., early stage in-house, scale-up outsourced)
Others

By End User

Hospitals and Specialty Clinics
Academic and Research Institutes
Biopharma and Biotech Companies
CDMOs and CROS
Government/Public Health Bodies
Others

By Region

North America
The US
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia and New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East and Africa
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Rest of South America

Geography Breakdown

North America commands a dominant position in the global market, holding over 39.50% of the total share. This leadership is largely driven by the region's strong and unparalleled innovation ecosystem, which fosters cutting-edge research and rapid development across various advanced fields. The region's regulatory environment, particularly in the United States, plays a crucial role in sustaining this momentum. In 2024, the U.S. Food and Drug Administration (FDA) approved nine new cell and gene therapy products, demonstrating a forward-looking and supportive stance toward emerging biotechnologies.
This positive regulatory climate has spurred an expansive research pipeline, with more than 2,500 active Investigational New Drug (IND) applications for cell and gene therapies currently filed with the FDA. Such a high volume of ongoing research initiatives reflects both the scientific community's enthusiasm and the regulatory agency's willingness to facilitate innovation. The robust pipeline not only signals future market growth but also attracts significant investment and talent to the region.

Leading Market Participants

ALLOGENE THERAPEUTICS
Amgen Inc.
Astellas Pharma Inc.
Atara Biotherapeutics, Inc.
Bayer AG
Biomarin
Bluebird Bio, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cellectis
Gilead Sciences, Inc.
Hoffmann-La Roche Ltd
ImmunoACT
Johnson & Johnson
Krystal Biotech, Inc
Novartis AG
Orchard Therapeutics plc
Sana Biotechnology
uniQure NV.
Vericel Corporation
Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Cell And Gene Therapy Market

Chapter 2. Report Description

2.1. Research Framework
- 2.1.1. Research Objective
- 2.1.2. Market Definitions
- 2.1.3. Market Segmentation
2.2. Research Methodology
- 2.2.1. Market Size Estimation
- 2.2.2. Qualitative Research
  - 2.2.2.1. Primary & Secondary Sources
- 2.2.3. Quantitative Research
  - 2.2.3.1. Primary & Secondary Sources
- 2.2.4. Breakdown of Primary Research Respondents, By Region
- 2.2.5. Data Triangulation
- 2.2.6. Assumption for Study

Chapter 3. Global Cell And Gene Therapy Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Material Provider
- 3.1.2. Manufacturer
- 3.1.3. Distributor
- 3.1.4. End User
3.2. Industry Outlook
- 3.2.1. Global Cell And Gene Therapy Market, 2020-2035 (in US$ Mn)
- 3.2.2. Overview of Cell and Gene Therapy: Market and Regional Developments
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Growth and Outlook
- 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
- 3.5.2. Price Trend Analysis, By Therapy Type
3.6. Market Attractiveness Analysis
- 3.6.1. By Therapy Type
- 3.6.2. By Region
- 3.6.3. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking
- 4.3.1. Key players - By Region

Chapter 5. Global Cell And Gene Therapy Market Analysis

5.1. Market Dynamics and Trends
- 5.1.1. Growth Drivers
- 5.1.2. Restraints
- 5.1.3. Opportunity
- 5.1.4. Key Trends
5.2. Market Opportunity Snapshot
5.3. By Therapy Type
- 5.3.1. Key Insights
- 5.3.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.3.2.1. Cell Therapy
    - 5.3.2.1.1. Stem Cell Therapy
    - 5.3.2.1.2. T-Cells
    - 5.3.2.1.3. Dendritic Cells
    - 5.3.2.1.4. NK Cells
  - 5.3.2.2. Gene Therapy
    - 5.3.2.2.1. In-vivGene Therapy
    - 5.3.2.2.2. Ex-vivGene Therapy
    - 5.3.2.2.3. Gene Editing Therapies
    - 5.3.2.2.4. RNA-Based Therapies
    - 5.3.2.2.5. Others
5.4. By Indication / Therapeutic Area
- 5.4.1. Key Insights
- 5.4.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.4.2.1. Oncology
  - 5.4.2.2. Solid Tumors
  - 5.4.2.3. Genetic Disorders
  - 5.4.2.4. Neurological Disorders
  - 5.4.2.5. Cardiovascular Diseases
  - 5.4.2.6. Ophthalmology
  - 5.4.2.7. Musculoskeletal / Orthopedic Disorders
  - 5.4.2.8. Infectious Diseases
  - 5.4.2.9. Metabolic Disorders
  - 5.4.2.10. Others
5.5. By Vector Type (Gene Delivery Method)
- 5.5.1. Key Insights
- 5.5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.5.2.1. Viral Vectors
    - 5.5.2.1.1. Adeno-Associated Virus (AAV)
    - 5.5.2.1.2. Lentivirus
    - 5.5.2.1.3. Retrovirus
    - 5.5.2.1.4. Herpes Simplex Virus (HSV)
    - 5.5.2.1.5. Adenovirus
    - 5.5.2.1.6. Others
  - 5.5.2.2. Non-Viral Vectors
    - 5.5.2.2.1. Lipid Nanoparticles (LNPs)
    - 5.5.2.2.2. Naked DNA/RNA Plasmids
    - 5.5.2.2.3. Electroporation
    - 5.5.2.2.4. Gene gun / microinjection
    - 5.5.2.2.5. CRISPR-Cas Delivery Systems (non-viral)
    - 5.5.2.2.6. Others
5.6. By Manufacturing Type
- 5.6.1. Key Insights
- 5.6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.6.2.1. In-house
  - 5.6.2.2. Contract Development & Manufacturing Organizations (CDMOs)
  - 5.6.2.3. Hybrid Models (e.g., early stage in-house, scale-up outsourced)
  - 5.6.2.4. Others
5.7. By End User
- 5.7.1. Key Insights
- 5.7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.7.2.1. Hospitals and Specialty Clinics
  - 5.7.2.2. Academic and Research Institutes
  - 5.7.2.3. Biopharma and Biotech Companies
  - 5.7.2.4. CDMOs and CROS
  - 5.7.2.5. Government/Public Health Bodies
  - 5.7.2.6. Others
5.8. By Region
- 5.8.1. Key Insights
- 5.8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.8.2.1. North America
    - 5.8.2.1.1. The U.S.
    - 5.8.2.1.2. Canada
    - 5.8.2.1.3. Mexico
  - 5.8.2.2. Europe
    - 5.8.2.2.1. Western Europe
      - 5.8.2.2.1.1. The UK
      - 5.8.2.2.1.2. Germany
      - 5.8.2.2.1.3. France
      - 5.8.2.2.1.4. Italy
      - 5.8.2.2.1.5. Spain
      - 5.8.2.2.1.6. Rest of Western Europe
    - 5.8.2.2.2. Eastern Europe
      - 5.8.2.2.2.1. Poland
      - 5.8.2.2.2.2. Russia
      - 5.8.2.2.2.3. Rest of Eastern Europe
  - 5.8.2.3. Asia Pacific
    - 5.8.2.3.1. China
    - 5.8.2.3.2. India
    - 5.8.2.3.3. Japan
    - 5.8.2.3.4. South Korea
    - 5.8.2.3.5. Australia & New Zealand
    - 5.8.2.3.6. ASEAN
    - 5.8.2.3.7. Rest of Asia Pacific
  - 5.8.2.4. Middle East & Africa
    - 5.8.2.4.1. UAE
    - 5.8.2.4.2. Saudi Arabia
    - 5.8.2.4.3. South Africa
    - 5.8.2.4.4. Rest of MEA
  - 5.8.2.5. South America
    - 5.8.2.5.1. Argentina
    - 5.8.2.5.2. Brazil
    - 5.8.2.5.3. Rest of South America

Chapter 6. North America Cell And Gene Therapy Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. By Therapy Type
- 6.2.2. By Indication / Therapeutic Area
- 6.2.3. By Vector Type (Gene Delivery Method)
- 6.2.4. By Manufacturing Type
- 6.2.5. By End User
- 6.2.6. By Region

Chapter 7. Europe Cell And Gene Therapy Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. By Therapy Type
- 7.2.2. By Indication / Therapeutic Area
- 7.2.3. By Vector Type (Gene Delivery Method)
- 7.2.4. By Manufacturing Type
- 7.2.5. By End User
- 7.2.6. By Region

Chapter 8. Asia Pacific Cell And Gene Therapy Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. By Therapy Type
- 8.2.2. By Indication / Therapeutic Area
- 8.2.3. By Vector Type (Gene Delivery Method)
- 8.2.4. By Manufacturing Type
- 8.2.5. By End User
- 8.2.6. By Region

Chapter 9. Middle East & Africa Cell And Gene Therapy Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. By Therapy Type
- 9.2.2. By Indication / Therapeutic Area
- 9.2.3. By Vector Type (Gene Delivery Method)
- 9.2.4. By Manufacturing Type
- 9.2.5. By End User
- 9.2.6. By Region

Chapter 10. South America Cell And Gene Therapy Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. By Therapy Type
- 10.2.2. By Indication / Therapeutic Area
- 10.2.3. By Vector Type (Gene Delivery Method)
- 10.2.4. By Manufacturing Type
- 10.2.5. By End User
- 10.2.6. By Region